Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 06, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions executed on December 4, 2006, involving the GlaxoSmithKline (US) Trust ("GSK US Trust"):
- Sales: The GSK US Trust sold 5,052 Ordinary Share ADRs on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of $52.86 per ADR.
- Transfers: The GSK US Trust transferred 10,015 Ordinary Share ADRs to participants in the GlaxoSmithKline Share Value Plan.
These transactions were advised to the Company on December 5, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses the notification of director and connected person interests in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADRs sold (5,052) and transferred (10,015) by the GSK US Trust.
- Confirm the transaction price of $52.86 per ADR.
- Note that Directors Dr J-P Garnier and Dr M M Slaoui hold interests in the GSK US Trust as potential beneficiaries alongside other employees or former employees of SmithKline Beecham Corporation.
- Confirm that this filing does not contain updated financial performance data for the period.